Cessatech A/S (NGM:CESSA)
8.28
-0.18 (-2.13%)
At close: Apr 11, 2025
Cessatech Company Description
Cessatech A/S, a pharmaceutical company, develops and commercializes medicines for the treatment of pediatric acute pain in Denmark.
The company’s lead product is CT001, an analgesic nasal spray for the treatment of acute and planned painful procedures in children.
It also develops CT002, a nasal spray for sedative procedures for children from 0-17 years of age; and CT003, a local anesthetic gel.
The company has a collaboration and license agreement with Ventis Pharma Corporation to develop and formulate pain management therapies.
Cessatech A/S was founded in 2020 and is based in Copenhagen, Denmark.
Cessatech A/S
Country | Denmark |
Founded | 2020 |
Industry | Pharmaceutical Preparations |
Employees | 4 |
CEO | Jes Trygved |
Contact Details
Address: Strandvejen 60 Copenhagen, 2900 Denmark | |
Phone | 45 93 87 23 09 |
Website | cessatech.com |
Stock Details
Ticker Symbol | CESSA |
Exchange | Nordic Growth Market |
Fiscal Year | January - December |
Reporting Currency | DKK |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Jes Trygved | Chief Executive Officer |